April 22, 2019
CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)
BELRAPZO is indicated for the treatment of patients with indolent B-cellnon-Hodgkin lymphoma (NHL) that has progressed during or within sixmonths of treatment with rituximab or a rituximab-containing regimen.